Home Using the likelihood ratio to evaluate allowable total error – an example with glycated hemoglobin (HbA1c)
Article
Licensed
Unlicensed Requires Authentication

Using the likelihood ratio to evaluate allowable total error – an example with glycated hemoglobin (HbA1c)

  • Arne Åsberg , Ingrid Hov Odsæter EMAIL logo , Sven Magnus Carlsen and Gustav Mikkelsen
Published/Copyright: April 18, 2015

Abstract

Background: Allowable total error is derived in many ways, often from data on biological variation in normal individuals. We present a new principle for evaluating allowable total error: What are the diagnostic consequences of allowable total errors in terms of errors in likelihood ratio (LR)? Glycated hemoglobin A1c in blood (HbA1c) in diagnosing diabetes mellitus is used as an example. Allowable total error for HbA1c is 3.0% derived from data on biological variation compared to 6.0% as defined by National Glycohemoglobin Standardization Program (NGSP).

Methods: We estimated a function for LR of HbA1c in diagnosing diabetes mellitus using logistic regression with a clinical database (n=572) where diabetes status was defined by WHO criteria. Then we estimated errors in LR that correspond to errors in the measurement of HbA1c.

Results: Measuring HbA1c 3% too low at HbA1c of 6.5 percentage points (the suggested diagnostic limit) gives a LR of 0.36 times the correct LR, while measuring HbA1c 3% too high gives a LR of 2.77 times the correct LR. The corresponding errors in LR for allowable total error of 6% are 0.13 and 7.69 times the correct LR, respectively.

Conclusions: These principles of evaluating allowable total error can be applied to any diagnostically used analyte where the distribution of the analyte’s concentration is known in patients with and without the disease in a clinically relevant population. In the example used, the allowable total error of 6% leads to very erroneous LRs, suggesting that the NGSP limits of ±6% are too liberal.


Corresponding author: Ingrid Hov Odsæter, Department of Clinical Chemistry, Trondheim University Hospital, 7006 Trondheim, Norway; and Faculty of Medicine, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, E-mail:

Acknowledgments

We thank Frode Width Gran for valuable assistance with data extraction.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Financial support: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet 2005;365:1500–5.10.1016/S0140-6736(05)66422-7Search in Google Scholar

2. Fraser CG. Biological variation: from principles to practice. Washington, DC: AACC Press, 2001.Search in Google Scholar

3. Klee GG. Establishment of outcome-related analytic performance goals. Clin Chem 2010;56:714–22.10.1373/clinchem.2009.133660Search in Google Scholar PubMed

4. Little RR, Rohlfing CL, Sacks DB. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011;57:205–14.10.1373/clinchem.2010.148841Search in Google Scholar PubMed

5. Gillett MJ. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–34. Clin Biochem Rev 2009;30:197–200.10.2337/dc09-9033Search in Google Scholar PubMed PubMed Central

6. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO Consultation. Geneva: World Health Organization, 2011:6–9.Search in Google Scholar

7. National Glycohemoglobin Standardization Program. NGSP News. Available from: http://www.ngsp.org/news.asp. Accessed 18 September, 2014.Search in Google Scholar

8. Westgard QC. Quality requirements. Available from: http://www.westgard.com/biodatabase1.htm. Accessed 18 September, 2014.Search in Google Scholar

9. Rohlfing CL, Parvin CA, Sacks DB, Little RR. Comparing analytic performance criteria: evaluation of HbA1c certification criteria as an example. Clin Chim Acta 2014;433:259–63.10.1016/j.cca.2014.03.034Search in Google Scholar PubMed PubMed Central

10. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. Geneva: World Health Organization, 2006:3.Search in Google Scholar

11. Martensson A, Rustad P, Lund H, Ossowicki H. Creatininium reference intervals for corrected methods. Scand J Clin Lab Invest 2004;64:439–41.10.1080/00365510410002832Search in Google Scholar PubMed

12. NOKLUS. Available from: http://www.noklus.no/English.aspx. Accessed 18 September, 2014.Search in Google Scholar

13. Labquality. Available from: http://www.labquality.fi/?lang=en. Accessed 18 September, 2014.Search in Google Scholar

14. Albert A. On the use and computation of likelihood ratios in clinical chemistry. Clin Chem 1982;28:1113–9.10.1093/clinchem/28.5.1113Search in Google Scholar

15. Royston P, Sauerbrei W. Building multivariable regression models with continuous covariates in clinical epidemiology – with an emphasis on fractional polynomials. Methods Inf Med 2005;44:561–71.10.1055/s-0038-1634008Search in Google Scholar

16. Oosterhuis WP. Gross overestimation of total allowable error based on biological variation. Clin Chem 2011;57:1334–6.10.1373/clinchem.2011.165308Search in Google Scholar PubMed

17. Bolann BJ, Asberg A. Analytical quality goals derived from the total deviation from patients’ homeostatic set points, with a margin for analytical errors. Scand J Clin Lab Invest 2004;64:443–50.10.1080/00365510410001167Search in Google Scholar PubMed

18. Weykamp CW, Mosca A, Gillery P, Panteghini M. The analytical goals for hemoglobin A(1c) measurement in IFCC units and National Glycohemoglobin Standardization Program units are different. Clin Chem 2011;57:1204–6.10.1373/clinchem.2011.162719Search in Google Scholar PubMed

19. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva: World Health Organization, 1999:52.Search in Google Scholar

20. Petersen PH, Jorgensen LG, Brandslund I, De Fine Olivarius N, Stahl M. Consequences of bias and imprecision in measurements of glucose and HbA1c for the diagnosis and prognosis of diabetes mellitus. Scand J Clin Lab Invest Suppl 2005;240:51–60.10.1080/00365510500236135Search in Google Scholar PubMed

21. Tankova T, Chakarova N, Dakovska L, Atanassova I. Assessment of HbA1c as a diagnostic tool in diabetes and prediabetes. Acta Diabetol 2012;49:371–8.10.1007/s00592-011-0334-5Search in Google Scholar PubMed

Received: 2014-11-17
Accepted: 2015-3-12
Published Online: 2015-4-18
Published in Print: 2015-8-1

©2015 by De Gruyter

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. New trends in the long and puzzling history of HbA1c
  4. Review
  5. Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges
  6. Opinion Paper
  7. Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients
  8. EFLM Original Article
  9. Compliance of blood sampling procedures with the CLSI H3-A6 guidelines: An observational study by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) working group for the preanalytical phase (WG-PRE)
  10. Genetics and Molecular Diagnostics
  11. Quantitative-fluorescent-PCR versus full karyotyping in prenatal diagnosis of common chromosome aneuploidies in southern Spain
  12. HIF1A and MIF as potential predictive mRNA biomarkers of pre-eclampsia: a longitudinal prospective study in high risk population
  13. General Clinical Chemistry and Laboratory Medicine
  14. Evidence of Crohn’s disease-related anti-glycoprotein 2 antibodies in patients with celiac disease
  15. Myocardial interleukin-6 in the setting of left ventricular mechanical assistance: relation with outcome and C-reactive protein
  16. Different methods to estimate serum free cortisol: a comparison during cortisol tetracosactide testing
  17. Automated immunoassays for the autoantibodies to carbamylated or citrullinated telopeptides of type I and II collagens
  18. Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohort
  19. Laboratory utilization improvement through a computer-aided algorithm developed with general practitioners
  20. Quantitation of 1α,25-dihydroxyvitamin D by LC-MS/MS using solid-phase extraction and fixed-charge derivitization in comparison to immunoextraction
  21. Reference Values and Biological Variations
  22. Establishment of trimester-specific thyroid stimulating hormone and free thyroxine reference interval in pregnant Chinese women using the Beckman Coulter UniCel™ DxI 600
  23. Cancer Diagnostics
  24. Expression of vascular endothelial factor-A, gelatinases (MMP-2, MMP-9) and TIMP-1 in uterine leiomyomas
  25. Influence of ABO type on global coagulation assay results: effect of coagulation factor VIII
  26. Diabetes
  27. Benchmarking by HbA1c in a national diabetes quality register – does measurement bias matter?
  28. Comparing HbA1c, fasting and 2-h plasma glucose for screening for abnormal glucose regulation in patients undergoing coronary angiography
  29. Erroneous HbA1c measurements in the presence of β-thalassemia and common Chinese hemoglobin variants
  30. Using the likelihood ratio to evaluate allowable total error – an example with glycated hemoglobin (HbA1c)
  31. Two novel haemoglobin variants that affect haemoglobin A1c measurement by ion-exchange chromatography
  32. Analytical performances of the D-100TM hemoglobin testing system (Bio-Rad) for HbA1c assay
  33. Letters to the Editors
  34. Glycation rate of haemoglobins S, C, D, E, J and G, and analytical interference on the measurement of HbA1c with affinity chromatography and capillary electrophoresis
  35. Hemoglobin Valme HBB:c.124T>G: a new hemoglobin variant with diminished oxygen affinity causes interference in hemoglobin A1c measurement in an automated ion-exchange HPLC method
  36. Hemoglobin A1c reported in units and diagnostic cut-offs in relation to the international recommendations
  37. Hemoglobin measurements in samples containing hemoglobin-based oxygen carriers
  38. Serologic false-positive reactions for syphilis in children of allergic purpura
  39. Exploration of the pre-analytical stability of β-lactam antibiotics in plasma and blood – implications for therapeutic drug monitoring and pharmacokinetic studies
  40. Fungal contamination of hyaluronidase solution mimicking fungal joint infection: a preanalytical pitfall in synovial fluid analysis
  41. Stroke and inherited thrombophilia in a Tunisian girl with sickle cell anemia
  42. Faecal haemoglobin concentrations do vary across geography as well as with age and sex: ramifications for colorectal cancer screening
Downloaded on 13.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2014-1125/html
Scroll to top button